Tremfya definition

Tremfya means, collectively, (a) the product known as TREMFYA® (guselkumab), and (b) any other product that contains the monoclonal antibody guselkumab either alone or in combination with one or more other active ingredients, including as covalently joined to another component, in each case of (a) and (b), in any preparation, strength, form (including pegylated versions), formulation (including whether short-acting or extended-release), administration or delivery route.
View Source

Examples of Tremfya in a sentence

  • Subject to the terms and conditions of the Centocor License Agreement, (i) Centocor and its Affiliates are required to pay the Centocor Royalty pursuant to Section 5.6 of the Centocor License Agreement on Centocor Net Sales of Tremfya in the Centocor Field in the Centocor Territory and (ii) the Seller has the right to receive the Centocor Royalty on Centocor Net Sales of Tremfya in the Centocor Field in the Centocor Territory.

  • Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Imbruvica, ▇▇▇▇▇▇▇▇ and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, ▇▇▇▇▇▇’s Nurtec ODT, ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Tremfya, Roche’s Evrysdi, ▇▇▇▇▇▇’s Trodelvy, and 10 development- stage product candidates.

  • The purpose of the Study is to further evaluate the safety of Stelara, Remicade, and Tremfya in patients with psoriasis.

  • Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Imbruvica, ▇▇▇▇▇▇▇▇ and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, ▇▇▇▇▇▇’s Nurtec ODT, ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Tremfya, Roche’s Evrysdi, ▇▇▇▇▇▇’s Trodelvy, and 17 development- stage product candidates.

  • The Seller shall not, without the prior written consent of the Buyer, send any material written notice or correspondence to GSK or Centocor with respect to any of the Acquired Assets, otilimab (in the case of GSK) or Tremfya (in the case of Centocor), and shall send such written notice or correspondence to any Licensee as the Buyer shall reasonably instruct.

  • Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Imbruvica, ▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, ▇▇▇▇▇▇’s Nurtec ODT, ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇’▇ Tremfya, Roche’s Evrysdi, ▇▇▇▇▇▇’s Trodelvy, and 12 development- stage product candidates.